Israel's CytoReason secures $80 million in funding to expand AI disease models

Nvidia, Pfizer, Thermo Fisher and OurCrowd invest to boost CytoReason's AI capabilities and data expansion

JERUSALEM:

Israel's CytoReason, which uses AI to develop disease models, said on Wednesday it had raised $80 million in a private funding round.

Nvidia, Pfizer, Thermo Fisher and venture capital investor OurCrowd participated in the round, CytoReason said.

The company said it aims to expand the application of its models into additional indications and grow its proprietary molecular and clinical data.

It also plans to establish an office in Cambridge, Massachusetts, later this year.

In 2022, Pfizer expanded its partnership with CytoReason with a $20 million investment that could reach $110 million by 2027.

"The rapid expansion of new technologies, like artificial

intelligence, holds tremendous potential to help transform what is possible in human health," said Mikael Dolsten, Pfizer's chief scientific officer.

"Our collaboration with CytoReason leverages its cutting-edge immunology multiomics platform to augment Pfizer’s own R&D capabilities and generate invaluable insights into new drug development pathways for patients."

CytoReason said six of the world’s top 10 pharma companies use its technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism, and other therapeutic areas using an AI platform of computational disease models.